Abstract:Background: Skeletal Stem Cells (SSCs) are required for skeletal development, homeostasis, and repair. The perspective of their wide application in regenerative medicine approaches has supported research in this field, even though so far results in the clinic have not reached expectations, possibly due also to partial knowledge of intrinsic, potentially actionable SSC regulatory factors. Among them, the pleiotropic cytokine RANKL, with essential roles also in bone biology, is a candidate deserving deep investigation. Methods: To dissect the role of the RANKL cytokine in SSC biology, we performed ex vivo characterization of SSCs and downstream progenitors (SSPCs) in mice lacking Rankl (Rankl-/-) by means of cytofluorimetric sorting and analysis of SSC populations from different skeletal compartments, gene expression analysis, and in vitro osteogenic differentiation. In addition, we assessed the effect of the pharmacological treatment with the anti-RANKL blocking antibody Denosumab (approved for therapy in patients with pathological bone loss) on the osteogenic potential of bone marrow-derived stromal cells from human healthy subjects (hBMSCs). Results: We found that, regardless of the ossification type of bone, osteochondral SSCs had a higher frequency and impaired differentiation along the osteochondrogenic lineage in Rankl-/- mice as compared to wild-type. Rankl-/- mice also had increased frequency of committed osteochondrogenic and adipogenic progenitor cells deriving from perivascular SSCs. These changes were not due to the peculiar bone phenotype of increased density caused by lack of osteoclast resorption (defined osteopetrosis); indeed, they were not found in another osteopetrotic mouse model, i.e., the oc/oc mouse, and were therefore not due to osteopetrosis per se. In addition, Rankl-/- SSCs and primary osteoblasts showed reduced mineralization capacity. Of note, hBMSCs treated in vitro with Denosumab had reduced osteogenic capacity compared to control cultures. Conclusions: We provide for the first time the characterization of SSPCs from mouse models of severe recessive osteopetrosis. We demonstrate that Rankl genetic deficiency in murine SSCs and functional blockade in hBMSCs reduce their osteogenic potential. Therefore, we propose that RANKL is an important regulatory factor of SSC features with translational relevance.

RANKL inhibition reduces lesional cellularity and Gα s variant expression and enables osteogenic maturation in fibrous dysplasia

RANKL Inhibition Halts Lesion Progression and Promotes Bone Remineralization in Mice with Fibrous Dysplasia.

Transcriptomic signature and pro-osteoclastic secreted factors of abnormal bone marrow stromal cells in fibrous dysplasia

A pathogenic role for brain-derived neurotrophic factor (BDNF) in fibrous dysplasia of bone

Denosumab in Patients with Fibrous Dysplasia Previously Treated with Bisphosphonates.

Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: A retrospective multicentric study

Expression of an Active Gαs Mutant in Skeletal Stem Cells is Sufficient and Necessary for Fibrous Dysplasia Initiation and Maintenance

The CREB–Smad6–Runx2 Axis Contributes to the Impaired Osteogenesis Potential of Bone Marrow Stromal Cells in Fibrous Dysplasia of Bone

Fibrous Dysplasia Involving Cranio-Facial Region Treated with Zolendronic Acid: A Single Institutional Experience and Review of Literature

Fibroblast Activation Protein Is Expressed by Altered Osteoprogenitors and Associated to Disease Burden in Fibrous Dysplasia

Rankl genetic deficiency and functional blockade undermine skeletal stem and progenitor cell differentiation

Wnt Pathway Inhibition with the Porcupine Inhibitor LGK974 Decreases Trabecular Bone but not Fibrosis in a Murine Model with Fibrotic Bone

Vitamin D Attenuates Fibrotic Properties of Fibrous Dysplasia-Derived Cells for the Transit towards Osteocytic Phenotype

Denosumab Attenuates Knee Osteoarthritis Progression by Inhibiting Synovial Inflammation Via the RANK/TRAF6/FSTL1 Signalling Pathway

12-Deoxyphorbol 13-Acetate Inhibits RANKL-induced Osteoclastogenesis Via the Attenuation of MAPK Signaling and NFATc1 Activation

PTHrP Modulates the Proliferation and Osteogenic Differentiation of Craniofacial Fibrous Dysplasia-Derived BMSCs

RANKL as a target for the treatment of osteoporosis

Pathophysiology and medical treatment of pain in fibrous dysplasia of bone

RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model

LDC000067 Suppresses RANKL-induced Osteoclastogenesis in Vitro and Prevents LPS-induced Osteolysis in Vivo.

RANKL Inhibitors Induce Osteonecrosis of the Jaw in Mice With Periapical Disease